Literature DB >> 34975266

SARS-CoV-2 Variants: Mutations and Effective Changes.

Gene Park1, Byeong Hee Hwang2,3.   

Abstract

One of the primary threats to the goal of controlling and eventually defeating SARS-CoV-2 is that of mutation. Recognizing this, a great amount of effort and dedicated study is being given to the matter. Due to the novel coronavirus's general prevalence and rate of mutation, this is an extremely dynamic area with constant new developments. Therefore, understanding the virus's pathogenesis and how mutations affect it is crucial. This review attempts to aid in understanding the currently most important strains and what primary changes they entail in connection to more specific mutations, and how they each affect infectivity, antigen resistance, and other properties. In an attempt to maintain relevance to the time at which this paper will be published, priority has been given to variants classified by the WHO and the CDC as of Sep. 23, 2021, as "Variants of Concern". Of particular interest in B.1.1.7, B.1.351, B.1.617.2, P.1 are the mutations affecting the Spike protein and Receptor Binding Domain, as they directly affect infectivity and susceptibility to neutralization. Certain mutations (D614G, E484K, N501Y, K417N, L452R and P681R) have appeared across several different strains, often accompanied by others that may be complementary working together to confer increased infectivity, fitness, or resistance to neutralization. We anticipate that the understanding of such COVID-19 mutations will, in the near future, prove important for diagnosis, treatment development, and vaccine development. © The Korean Society for Biotechnology and Bioengineering and Springer 2021.

Entities:  

Keywords:  SARS-CoV-2; infectivity; mutation; neutralization; variants

Year:  2021        PMID: 34975266      PMCID: PMC8713537          DOI: 10.1007/s12257-021-0327-3

Source DB:  PubMed          Journal:  Biotechnol Bioprocess Eng        ISSN: 1226-8372            Impact factor:   2.836


  60 in total

1.  Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.

Authors:  Sandile Cele; Inbal Gazy; Laurelle Jackson; Shi-Hsia Hwa; Houriiyah Tegally; Gila Lustig; Jennifer Giandhari; Sureshnee Pillay; Eduan Wilkinson; Yeshnee Naidoo; Farina Karim; Yashica Ganga; Khadija Khan; Mallory Bernstein; Alejandro B Balazs; Bernadett I Gosnell; Willem Hanekom; Mahomed-Yunus S Moosa; Richard J Lessells; Tulio de Oliveira; Alex Sigal
Journal:  Nature       Date:  2021-03-29       Impact factor: 49.962

2.  Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion.

Authors:  Donald J Benton; Antoni G Wrobel; Pengqi Xu; Chloë Roustan; Stephen R Martin; Peter B Rosenthal; John J Skehel; Steven J Gamblin
Journal:  Nature       Date:  2020-09-17       Impact factor: 49.962

3.  SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity.

Authors:  Seiya Ozono; Yanzhao Zhang; Hirotaka Ode; Kaori Sano; Toong Seng Tan; Kazuo Imai; Kazuyasu Miyoshi; Satoshi Kishigami; Takamasa Ueno; Yasumasa Iwatani; Tadaki Suzuki; Kenzo Tokunaga
Journal:  Nat Commun       Date:  2021-02-08       Impact factor: 14.919

4.  SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.

Authors:  Qianqian Li; Jianhui Nie; Jiajing Wu; Li Zhang; Ruxia Ding; Haixin Wang; Yue Zhang; Tao Li; Shuo Liu; Mengyi Zhang; Chenyan Zhao; Huan Liu; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Junkai Liu; Haoyu Liang; Yi Shi; Yuelei Shen; Liangzhi Xie; Linqi Zhang; Xiaowang Qu; Wenbo Xu; Weijin Huang; Youchun Wang
Journal:  Cell       Date:  2021-02-23       Impact factor: 41.582

5.  Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.

Authors:  Lin Cheng; Shuo Song; Bing Zhou; Xiangyang Ge; Jiazhen Yu; Mingxia Zhang; Bin Ju; Zheng Zhang
Journal:  Virol J       Date:  2021-04-28       Impact factor: 4.099

6.  A human coronavirus evolves antigenically to escape antibody immunity.

Authors:  Rachel T Eguia; Katharine H D Crawford; Terry Stevens-Ayers; Laurel Kelnhofer-Millevolte; Alexander L Greninger; Janet A Englund; Michael J Boeckh; Jesse D Bloom
Journal:  PLoS Pathog       Date:  2021-04-08       Impact factor: 6.823

7.  N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2.

Authors:  Fang Tian; Bei Tong; Liang Sun; Shengchao Shi; Bin Zheng; Zibin Wang; Xianchi Dong; Peng Zheng
Journal:  Elife       Date:  2021-08-20       Impact factor: 8.140

8.  SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.

Authors:  Petra Mlcochova; Steven A Kemp; Mahesh Shanker Dhar; Partha Rakshit; Anurag Agrawal; Ravindra K Gupta; Guido Papa; Bo Meng; Isabella A T M Ferreira; Rawlings Datir; Dami A Collier; Anna Albecka; Sujeet Singh; Rajesh Pandey; Jonathan Brown; Jie Zhou; Niluka Goonawardane; Swapnil Mishra; Charles Whittaker; Thomas Mellan; Robin Marwal; Meena Datta; Shantanu Sengupta; Kalaiarasan Ponnusamy; Venkatraman Srinivasan Radhakrishnan; Adam Abdullahi; Oscar Charles; Partha Chattopadhyay; Priti Devi; Daniela Caputo; Tom Peacock; Chand Wattal; Neeraj Goel; Ambrish Satwik; Raju Vaishya; Meenakshi Agarwal; Antranik Mavousian; Joo Hyeon Lee; Jessica Bassi; Chiara Silacci-Fegni; Christian Saliba; Dora Pinto; Takashi Irie; Isao Yoshida; William L Hamilton; Kei Sato; Samir Bhatt; Seth Flaxman; Leo C James; Davide Corti; Luca Piccoli; Wendy S Barclay
Journal:  Nature       Date:  2021-09-06       Impact factor: 49.962

9.  D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.

Authors:  Drew Weissman; Mohamad-Gabriel Alameh; Thushan de Silva; Paul Collini; Hailey Hornsby; Rebecca Brown; Celia C LaBranche; Robert J Edwards; Laura Sutherland; Sampa Santra; Katayoun Mansouri; Sophie Gobeil; Charlene McDanal; Norbert Pardi; Nick Hengartner; Paulo J C Lin; Ying Tam; Pamela A Shaw; Mark G Lewis; Carsten Boesler; Uğur Şahin; Priyamvada Acharya; Barton F Haynes; Bette Korber; David C Montefiori
Journal:  Cell Host Microbe       Date:  2020-12-01       Impact factor: 31.316

10.  Preliminary Structural Data Revealed That the SARS-CoV-2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the Wild Type to Enhance the Infectivity.

Authors:  Abbas Khan; Dong-Qing Wei; Kafila Kousar; Jehad Abubaker; Sajjad Ahmad; Javaid Ali; Fahd Al-Mulla; Syed Shujait Ali; N Nizam-Uddin; Abrar Mohammad Sayaf; Anwar Mohammad
Journal:  Chembiochem       Date:  2021-06-23       Impact factor: 3.164

View more
  2 in total

Review 1.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Authors:  Cong Sun; Chu Xie; Guo-Long Bu; Lan-Yi Zhong; Mu-Sheng Zeng
Journal:  Signal Transduct Target Ther       Date:  2022-06-28

2.  Identification of antigens recognized by salivary IgA using microbial protein microarrays.

Authors:  Koji Hamuro; Hiroshi Saito; Takao Saito; Noriyuki Kohda
Journal:  Biosci Microbiota Food Health       Date:  2022-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.